Table 4

Univariate analysis of patients with breast IMPC

Factors	DFS			OS
Factors	HR	95%CI	P	HR	95%CI	P
Age (≤ 52 vs. > 52)	0.717	0.361–1.422	0.341	0.708	0.158–3.166	0.652
Tumor size
(T1–T2 vs. T3–T4)	1.557	0.705–3.436	0.273	0.770	0.093–6.400	0.809
Histological grade
(I vs. II vs. III)	1.947	1.086–3.489	0.025*	0.376	0.107–1.318	0.126
ER (negative vs. positive)	1.567	0.752–3.264	0.231	3.489	0.420–29.010	0.248
PR (negative vs. positive)	0.859	0.439–1.681	0.657	0.759	0.170–3.392	0.718
HER2 (negative vs. positive)	1.100	0.562–2.152	0.781	0.642	0.124–3.314	0.597
sLe^x in cytomembrane	4.137	2.019–8.478	< 0.001*	7.247	0.872–60.200	0.067
sLe^x in cytoplasm	4.207	2.101–8.422	< 0.001*	4.114	0.798–21.211	0.091
EMA in cytomembrane	0.769	0.382–1.548	0.462	2.278	0.512–10.252	0.278
EMA in cytoplasm	0.812	0.286–2.302	0.695	1.442	0.173–12.011	0.735
Chemotherapy	0.993	0.300–3.286	0.991	0.445	0.052–3.813	0.460
Radiotherapy	2.016	0.987–4.117	0.054	4.277	0.783–23.376	0.094
Endocrine therapy	0.658	0.295–1.466	0.306	0.836	0.153–4.579	0.837
Lymph nodes
(N0 vs. N1 vs. N2 vs. N3)	1.480	1.106–1.981	0.008*	1.756	0.917–3.362	0.090

*P < 0.05 was considered statistically significant. DFS, disease-free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal factor receptor 2; IMPC, invasive micropapillary carcinoma; IDC-NOS, invasive ductal carcinoma, non-special type; sLe^x, sialylated Lewis glycoprotein X; EMA, epithelial membrane antigen. P < 0.05, calculated with the log-rank test.